{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:45:25Z","timestamp":1759776325751},"reference-count":28,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1111\/jcpt.12651","type":"journal-article","created":{"date-parts":[[2017,11,18]],"date-time":"2017-11-18T04:26:40Z","timestamp":1510979200000},"page":"342-347","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease"],"prefix":"10.1155","volume":"43","author":[{"given":"L.-L.","family":"Shang","sequence":"first","affiliation":[{"name":"Department of Intensive Medicine; The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine; Ha'erbin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.-D.","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiology; The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine; Ha'erbin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-Y.","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology; The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine; Ha'erbin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-J.","family":"Quan","sequence":"additional","affiliation":[{"name":"Department of Intensive Medicine; The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine; Ha'erbin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.-G.","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Cardiology; General Hospital of Heilongjiang Agricultural Reclamation Bureau; Ha'erbin China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"key":"10.1111\/jcpt.12651-BIB0001|jcpt12651-cit-0001","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2337\/dc16-0273","article-title":"Epidemiology of diabetes-status of a pandemic and issues around metabolic surgery","volume":"39","author":"Zimmet","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12651-BIB0002|jcpt12651-cit-0002","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes","volume":"372","author":"Hayward","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12651-BIB0003|jcpt12651-cit-0003","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/CIR.0000000000000350","article-title":"Heart disease and stroke statistics-2016 update: a report from the American heart association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12651-BIB0004|jcpt12651-cit-0004","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12651-BIB0005|jcpt12651-cit-0005","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.109.913376","article-title":"Diabetes and antiplatelet therapy in acute coronary syndrome","volume":"123","author":"Ferreiro","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12651-BIB0006|jcpt12651-cit-0006","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1253\/circj.CJ-16-0208","article-title":"Antithrombotic therapy for secondary prevention in patients with diabetes mellitus and coronary artery disease","volume":"80","author":"Park","year":"2016","journal-title":"Circ J"},{"key":"10.1111\/jcpt.12651-BIB0007|jcpt12651-cit-0007","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/2012.jama.10779","article-title":"Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes","volume":"308","author":"Andersson","year":"2012","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12651-BIB0008|jcpt12651-cit-0008","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.jacc.2008.07.068","article-title":"Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo","volume":"52","author":"Erlinge","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12651-BIB0009|jcpt12651-cit-0009","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12651-BIB0010|jcpt12651-cit-0010","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12651-BIB0011|jcpt12651-cit-0011","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12651-BIB0012|jcpt12651-cit-0012","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1111\/jcpt.12651-BIB0013|jcpt12651-cit-0013","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc16-S005","article-title":"Classification and diagnosis of diabetes","volume":"39","author":"American Diabetes Association. 2","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12651-BIB0014|jcpt12651-cit-0014","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14656566.2016.1110145","article-title":"Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin\/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case-control study","volume":"17","author":"Liu","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/jcpt.12651-BIB0015|jcpt12651-cit-0015","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/09537104.2012.689037","article-title":"Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance","volume":"23","author":"Tsantes","year":"2012","journal-title":"Platelets"},{"key":"10.1111\/jcpt.12651-BIB0016|jcpt12651-cit-0016","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacc.2007.04.051","article-title":"Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry","volume":"50","author":"Machecourt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12651-BIB0017|jcpt12651-cit-0017","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jacc.2003.04.004","article-title":"Short- and long-term results after multivessel stenting in diabetic patients","volume":"43","author":"Mehran","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12651-BIB0018|jcpt12651-cit-0018","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.298.7.765","article-title":"Diabetes and mortality following acute coronary syndromes","volume":"298","author":"Donahoe","year":"2007","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12651-BIB0019|jcpt12651-cit-0019","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1111\/jcpt.12651-BIB0020|jcpt12651-cit-0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12933-016-0362-0","article-title":"Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus","volume":"15","author":"Zhang","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1111\/jcpt.12651-BIB0021|jcpt12651-cit-0021","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12933-017-0543-5","article-title":"PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology","volume":"16","author":"Cerrato","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1111\/jcpt.12651-BIB0022|jcpt12651-cit-0022","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.amjcard.2014.12.029","article-title":"Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity","volume":"115","author":"Lhermusier","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1111\/jcpt.12651-BIB0023|jcpt12651-cit-0023","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1093\/eurheartj\/ehv744","article-title":"A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study","volume":"37","author":"Rollini","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1111\/jcpt.12651-BIB0024|jcpt12651-cit-0024","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/dc12-2510","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes","volume":"36","author":"Alexopoulos","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12651-BIB0025|jcpt12651-cit-0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1161\/CIRCULATIONAHA.116.023743","article-title":"Clopidogrel versus ticagrelor for antiplatelet maintenance in diabetic patients treated with percutaneous coronary intervention: results of the CLOTILDIA study (clopidogrel high dose versus ticagrelor for antiplatelet maintenance in diabetic patients)","volume":"134","author":"Mangiacapra","year":"2016","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12651-BIB0026|jcpt12651-cit-0026","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/CIRCULATIONAHA.116.023402","article-title":"Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (optimizing antiplatelet therapy in diabetes mellitus)-4 study","volume":"134","author":"Franchi","year":"2016","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12651-BIB0027|jcpt12651-cit-0027","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/eurheartj\/ehq494","article-title":"A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial","volume":"32","author":"Angiolillo","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1111\/jcpt.12651-BIB0028|jcpt12651-cit-0028","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1160\/TH13-05-0384","article-title":"Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study","volume":"111","author":"Laine","year":"2014","journal-title":"Thromb Haemost"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12651","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12651\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:25Z","timestamp":1671818605000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12651","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11,17]]}}}